Form 4: Neogenomics Director Alison L. Hannah Reports Stock Option and Restricted Stock Unit Transactions
SEC Form 4 Filing
Director Alison L. Hannah reports acquisition of stock options and restricted stock units in Neogenomics.
Summary
- On June 4, 2024, Alison L. Hannah, a director of Neogenomics Inc., filed a Form 4 with the SEC.
- The report details changes in beneficial ownership of Neogenomics securities.
- Hannah acquired 8,672 stock options with an exercise price of $13.71 on June 1, 2024, exercisable from June 1, 2025, and expiring on June 1, 2034.
- Additionally, Hannah acquired 12,254 restricted stock units on June 1, 2024, vesting on June 1, 2025.
- Hannah directly owns 107,433 shares of common stock.
- Hannah also holds various stock options with different exercise prices and expiration dates, including 3,017 options at $11.60 (expiring 06/01/2023), 4,269 options at $22.52 (expiring 06/06/2026), 3,448 options at $28.54 (expiring 05/28/2027), 3,714 options at $40.9 (expiring 06/02/2028), 13,882 options at $8.1 (expiring 06/10/2029), and 8,353 options at $14.82 (expiring 08/10/2033).
- Hannah also holds 11,336 restricted stock units that do not expire once vested.
Sentiment
Score: 5
Explanation: The document is a neutral report of insider transactions. It doesn't inherently convey positive or negative sentiment about the company's prospects.
Positives
- The acquisition of stock options and restricted stock units by a director could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors and their holdings in the company's stock.
Comparison to Industry Standards
- Insider transactions are a common occurrence in publicly traded companies like Neogenomics.
- Comparing the size and frequency of these transactions to those of directors at similar companies (e.g., Exact Sciences, Guardant Health) can provide insights into the relative alignment of management's interests with shareholders.
Stakeholder Impact
- The disclosure of insider transactions provides transparency to shareholders regarding the actions of company directors.
- These transactions can influence investor sentiment and potentially impact the stock price.
Key Dates
| Date | Description |
|---|---|
| 06/01/2019 | Date of stock option grant with exercise price of $11.60 and expiration date of 06/01/2023. |
| 06/01/2023 | Expiration date of stock option grant with exercise price of $11.60. |
| 06/06/2020 | Date of stock option grant with exercise price of $22.52 and expiration date of 06/06/2026. |
| 05/28/2021 | Date of stock option grant with exercise price of $28.54 and expiration date of 05/28/2027. |
| 06/02/2022 | Date of stock option grant with exercise price of $40.9 and expiration date of 06/02/2028. |
| 06/10/2023 | Date of stock option grant with exercise price of $8.1 and expiration date of 06/10/2029. |
| 06/01/2024 | Date of transaction: acquisition of stock options and restricted stock units; Date of stock option grant with exercise price of $13.71 and expiration date of 06/01/2034; Date of restricted stock unit grant vesting on 06/01/2025. |
| 06/04/2024 | Date of Form 4 filing. |
| 08/10/2024 | Date of stock option grant with exercise price of $14.82 and expiration date of 08/10/2033; Date of restricted stock unit grant. |
| 06/01/2025 | Vesting date for restricted stock units acquired on 06/01/2024; Exercisable date for stock options acquired on 06/01/2024. |
| 06/06/2026 | Expiration date of stock option grant with exercise price of $22.52. |
| 05/28/2027 | Expiration date of stock option grant with exercise price of $28.54. |
| 06/02/2028 | Expiration date of stock option grant with exercise price of $40.9. |
| 06/10/2029 | Expiration date of stock option grant with exercise price of $8.1. |
| 08/10/2033 | Expiration date of stock option grant with exercise price of $14.82. |
| 06/01/2034 | Expiration date of stock option grant with exercise price of $13.71. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.